- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call Transcript
Good morning, ladies and gentlemen. And welcome to the Dicerna Pharmaceuticals Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded at the company's request.
I will now turn the call over to your host, [Abby Weissman], representing Dicerna Pharmaceuticals. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us for Dicerna's corporate update related to its collaboration with Novo Nordisk announced earlier this morning.
This morning, Dicerna and Novo Nordisk issued a press release announcing the companies have entered an agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases. The press release may be found under the Investors & Media tab on our website at www.dicerna.com. You may also listen to this conference call via webcast on our website, which will be archived for 30 days, beginning approximately 2 hours after the call is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |